| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 431 | 2024 | 3164 | 50.700 |
Why?
|
| Kidney Neoplasms | 420 | 2024 | 4249 | 43.360 |
Why?
|
| Anilides | 31 | 2024 | 411 | 7.890 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 118 | 2024 | 11742 | 6.960 |
Why?
|
| Antineoplastic Agents | 138 | 2024 | 13639 | 6.670 |
Why?
|
| Pyrroles | 52 | 2018 | 1125 | 6.340 |
Why?
|
| Vascular Endothelial Growth Factor A | 63 | 2023 | 3492 | 5.600 |
Why?
|
| Nephrectomy | 48 | 2024 | 937 | 5.590 |
Why?
|
| Indoles | 52 | 2018 | 1833 | 5.560 |
Why?
|
| Angiogenesis Inhibitors | 45 | 2022 | 2047 | 4.860 |
Why?
|
| Pyridines | 46 | 2024 | 2875 | 4.780 |
Why?
|
| Molecular Targeted Therapy | 58 | 2024 | 2811 | 4.430 |
Why?
|
| Carcinoma, Transitional Cell | 34 | 2023 | 782 | 4.000 |
Why?
|
| Phenylurea Compounds | 35 | 2024 | 529 | 3.910 |
Why?
|
| Urologic Neoplasms | 27 | 2020 | 314 | 3.890 |
Why?
|
| Urinary Bladder Neoplasms | 44 | 2023 | 2223 | 3.460 |
Why?
|
| Protein Kinase Inhibitors | 62 | 2023 | 5671 | 3.440 |
Why?
|
| Prostatic Neoplasms | 110 | 2023 | 11118 | 3.260 |
Why?
|
| Neoplasm Metastasis | 84 | 2024 | 4915 | 3.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 17 | 2018 | 664 | 2.990 |
Why?
|
| Disease-Free Survival | 79 | 2024 | 6814 | 2.730 |
Why?
|
| Antibodies, Monoclonal | 39 | 2023 | 9177 | 2.550 |
Why?
|
| Niacinamide | 27 | 2017 | 413 | 2.540 |
Why?
|
| TOR Serine-Threonine Kinases | 32 | 2022 | 2057 | 2.480 |
Why?
|
| Humans | 754 | 2024 | 761504 | 2.360 |
Why?
|
| Proto-Oncogene Proteins c-met | 11 | 2020 | 571 | 2.280 |
Why?
|
| Neoplasms | 78 | 2024 | 22170 | 2.270 |
Why?
|
| Androgen Antagonists | 33 | 2023 | 1410 | 2.250 |
Why?
|
| Indazoles | 31 | 2024 | 304 | 2.240 |
Why?
|
| Aged | 345 | 2024 | 169289 | 2.210 |
Why?
|
| Middle Aged | 353 | 2024 | 220895 | 2.180 |
Why?
|
| Survival Analysis | 71 | 2024 | 10090 | 2.150 |
Why?
|
| Cystectomy | 14 | 2018 | 634 | 2.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 8 | 2024 | 1136 | 2.110 |
Why?
|
| Male | 450 | 2024 | 360804 | 2.070 |
Why?
|
| Immunotherapy | 39 | 2024 | 4652 | 1.940 |
Why?
|
| Quinolines | 8 | 2024 | 764 | 1.930 |
Why?
|
| Sirolimus | 17 | 2023 | 1533 | 1.910 |
Why?
|
| Sulfonamides | 25 | 2024 | 1978 | 1.840 |
Why?
|
| Urothelium | 13 | 2017 | 269 | 1.830 |
Why?
|
| Kaplan-Meier Estimate | 48 | 2024 | 6484 | 1.730 |
Why?
|
| Prognosis | 108 | 2024 | 29625 | 1.730 |
Why?
|
| Treatment Outcome | 155 | 2024 | 64680 | 1.690 |
Why?
|
| Clinical Trials, Phase II as Topic | 27 | 2024 | 629 | 1.690 |
Why?
|
| Female | 339 | 2024 | 392644 | 1.670 |
Why?
|
| Pyrimidines | 28 | 2024 | 3028 | 1.660 |
Why?
|
| Aged, 80 and over | 144 | 2024 | 58976 | 1.630 |
Why?
|
| Benzenesulfonates | 16 | 2012 | 166 | 1.600 |
Why?
|
| Prostate-Specific Antigen | 30 | 2023 | 2469 | 1.560 |
Why?
|
| Bone Neoplasms | 10 | 2019 | 2529 | 1.550 |
Why?
|
| Clinical Trials, Phase III as Topic | 25 | 2024 | 857 | 1.470 |
Why?
|
| Prostatectomy | 29 | 2019 | 1824 | 1.450 |
Why?
|
| Survival Rate | 59 | 2024 | 12725 | 1.380 |
Why?
|
| Vinblastine | 8 | 2019 | 488 | 1.370 |
Why?
|
| Antineoplastic Agents, Hormonal | 17 | 2023 | 1520 | 1.330 |
Why?
|
| Retrospective Studies | 141 | 2024 | 80636 | 1.230 |
Why?
|
| SEER Program | 40 | 2023 | 1450 | 1.230 |
Why?
|
| Chemotherapy, Adjuvant | 28 | 2024 | 3514 | 1.190 |
Why?
|
| Neoplasm Staging | 62 | 2024 | 11121 | 1.170 |
Why?
|
| Triazines | 2 | 2020 | 311 | 1.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 7 | 2024 | 305 | 1.110 |
Why?
|
| Adult | 169 | 2024 | 221177 | 1.110 |
Why?
|
| Cisplatin | 14 | 2020 | 1651 | 1.100 |
Why?
|
| Mutation | 46 | 2024 | 30052 | 1.080 |
Why?
|
| Carcinoma, Papillary | 6 | 2015 | 785 | 1.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 32 | 2024 | 8547 | 1.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2020 | 546 | 1.050 |
Why?
|
| Medical Oncology | 15 | 2024 | 2321 | 1.030 |
Why?
|
| Healthcare Disparities | 18 | 2023 | 3358 | 0.990 |
Why?
|
| Follow-Up Studies | 63 | 2024 | 39106 | 0.980 |
Why?
|
| Drug Resistance, Neoplasm | 15 | 2021 | 5305 | 0.970 |
Why?
|
| Carbonic Anhydrases | 3 | 2024 | 108 | 0.950 |
Why?
|
| Neoplasm Recurrence, Local | 25 | 2023 | 9280 | 0.950 |
Why?
|
| Neoadjuvant Therapy | 19 | 2019 | 2827 | 0.950 |
Why?
|
| Databases, Factual | 42 | 2024 | 7967 | 0.940 |
Why?
|
| Pyrazines | 3 | 2020 | 1201 | 0.930 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 6 | 2021 | 1626 | 0.930 |
Why?
|
| Germ-Line Mutation | 7 | 2022 | 1858 | 0.910 |
Why?
|
| Endogenous Retroviruses | 2 | 2022 | 111 | 0.900 |
Why?
|
| Indenes | 1 | 2024 | 59 | 0.900 |
Why?
|
| Randomized Controlled Trials as Topic | 39 | 2022 | 10209 | 0.880 |
Why?
|
| Protective Agents | 2 | 2014 | 150 | 0.870 |
Why?
|
| Imidazoles | 8 | 2017 | 1180 | 0.870 |
Why?
|
| Clinical Trials as Topic | 38 | 2021 | 8002 | 0.850 |
Why?
|
| Chromosomes, Human, X | 4 | 2024 | 321 | 0.830 |
Why?
|
| Salvage Therapy | 13 | 2019 | 1264 | 0.830 |
Why?
|
| Combined Modality Therapy | 26 | 2024 | 8529 | 0.820 |
Why?
|
| Urogenital Neoplasms | 2 | 2020 | 131 | 0.810 |
Why?
|
| Proportional Hazards Models | 41 | 2023 | 12463 | 0.790 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2014 | 629 | 0.770 |
Why?
|
| Translocation, Genetic | 5 | 2024 | 1393 | 0.750 |
Why?
|
| Immunoconjugates | 4 | 2023 | 954 | 0.740 |
Why?
|
| Taxoids | 7 | 2017 | 668 | 0.720 |
Why?
|
| Ubiquitin Thiolesterase | 6 | 2021 | 455 | 0.710 |
Why?
|
| Genomics | 19 | 2023 | 5821 | 0.700 |
Why?
|
| Therapies, Investigational | 1 | 2021 | 111 | 0.690 |
Why?
|
| Adrenocortical Carcinoma | 3 | 2016 | 88 | 0.680 |
Why?
|
| Neoplasms, Second Primary | 7 | 2018 | 1052 | 0.670 |
Why?
|
| Testicular Neoplasms | 7 | 2018 | 799 | 0.660 |
Why?
|
| Interleukin-8 | 2 | 2020 | 695 | 0.660 |
Why?
|
| Pandemics | 15 | 2023 | 8654 | 0.650 |
Why?
|
| Carcinoma | 9 | 2023 | 2330 | 0.640 |
Why?
|
| Lymphocytes | 5 | 2023 | 2612 | 0.630 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 210 | 0.630 |
Why?
|
| Early Detection of Cancer | 13 | 2023 | 3201 | 0.620 |
Why?
|
| Immunologic Factors | 6 | 2021 | 1589 | 0.620 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 3084 | 0.620 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 66 | 0.610 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 3204 | 0.610 |
Why?
|
| Brain Neoplasms | 11 | 2023 | 9031 | 0.600 |
Why?
|
| Radiosurgery | 3 | 2023 | 1342 | 0.600 |
Why?
|
| Melanoma | 11 | 2024 | 5709 | 0.590 |
Why?
|
| Radium | 1 | 2018 | 72 | 0.590 |
Why?
|
| Risk Factors | 73 | 2023 | 74206 | 0.580 |
Why?
|
| Time Factors | 45 | 2024 | 39967 | 0.570 |
Why?
|
| Indans | 1 | 2017 | 92 | 0.570 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 10 | 2021 | 1092 | 0.560 |
Why?
|
| Quality of Life | 19 | 2024 | 13367 | 0.550 |
Why?
|
| Drug Administration Schedule | 13 | 2019 | 4853 | 0.550 |
Why?
|
| Thromboembolism | 3 | 2012 | 995 | 0.540 |
Why?
|
| Neoplasm Proteins | 9 | 2019 | 3617 | 0.530 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2016 | 161 | 0.530 |
Why?
|
| Lung Neoplasms | 16 | 2024 | 13380 | 0.530 |
Why?
|
| Deoxycytidine | 3 | 2017 | 877 | 0.530 |
Why?
|
| Gene Expression Profiling | 19 | 2021 | 9420 | 0.510 |
Why?
|
| Antigens, Neoplasm | 5 | 2024 | 1993 | 0.510 |
Why?
|
| Tumor Burden | 6 | 2022 | 1893 | 0.510 |
Why?
|
| Disease Progression | 26 | 2023 | 13506 | 0.500 |
Why?
|
| Hand Joints | 1 | 2016 | 58 | 0.500 |
Why?
|
| Young Adult | 37 | 2024 | 59243 | 0.500 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2021 | 2803 | 0.500 |
Why?
|
| Orchiectomy | 6 | 2016 | 463 | 0.500 |
Why?
|
| Isoflavones | 2 | 2006 | 136 | 0.500 |
Why?
|
| Sulfones | 1 | 2017 | 448 | 0.490 |
Why?
|
| Oligonucleotides | 1 | 2018 | 582 | 0.490 |
Why?
|
| Standard of Care | 2 | 2018 | 551 | 0.480 |
Why?
|
| Patient Selection | 10 | 2021 | 4244 | 0.480 |
Why?
|
| Registries | 10 | 2023 | 8224 | 0.480 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2021 | 10766 | 0.470 |
Why?
|
| United States | 71 | 2023 | 72334 | 0.470 |
Why?
|
| Angiotensins | 1 | 2015 | 143 | 0.470 |
Why?
|
| Neutrophils | 5 | 2022 | 3767 | 0.470 |
Why?
|
| Tumor Microenvironment | 11 | 2024 | 3877 | 0.460 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 4 | 2024 | 318 | 0.460 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2021 | 151 | 0.460 |
Why?
|
| Risk Assessment | 43 | 2024 | 23995 | 0.450 |
Why?
|
| Double-Blind Method | 10 | 2024 | 12341 | 0.440 |
Why?
|
| ABO Blood-Group System | 2 | 2015 | 380 | 0.440 |
Why?
|
| Cohort Studies | 39 | 2023 | 41487 | 0.430 |
Why?
|
| Risk | 14 | 2018 | 9610 | 0.430 |
Why?
|
| Infection Control | 1 | 2020 | 981 | 0.420 |
Why?
|
| High-Throughput Nucleotide Sequencing | 13 | 2021 | 3639 | 0.420 |
Why?
|
| Logistic Models | 23 | 2019 | 13255 | 0.420 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 592 | 0.420 |
Why?
|
| Epigenomics | 5 | 2024 | 943 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2011 | 748 | 0.410 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 698 | 0.410 |
Why?
|
| Prospective Studies | 37 | 2024 | 54425 | 0.400 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 532 | 0.400 |
Why?
|
| Uveitis | 1 | 2016 | 395 | 0.400 |
Why?
|
| Administration, Oral | 9 | 2024 | 4021 | 0.390 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2013 | 270 | 0.390 |
Why?
|
| Renin-Angiotensin System | 2 | 2022 | 737 | 0.390 |
Why?
|
| Nomograms | 3 | 2020 | 230 | 0.390 |
Why?
|
| Intention to Treat Analysis | 3 | 2021 | 413 | 0.380 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2024 | 5315 | 0.380 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2014 | 410 | 0.380 |
Why?
|
| Adenocarcinoma | 9 | 2024 | 6346 | 0.380 |
Why?
|
| Vinca Alkaloids | 1 | 2011 | 36 | 0.380 |
Why?
|
| Hyponatremia | 1 | 2013 | 279 | 0.370 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 619 | 0.370 |
Why?
|
| Nuclear Proteins | 6 | 2022 | 5796 | 0.370 |
Why?
|
| Signal Transduction | 27 | 2022 | 23445 | 0.360 |
Why?
|
| Immunohistochemistry | 16 | 2019 | 11076 | 0.360 |
Why?
|
| DNA-Binding Proteins | 11 | 2022 | 9606 | 0.360 |
Why?
|
| Incidence | 27 | 2023 | 21353 | 0.360 |
Why?
|
| Arthritis | 1 | 2016 | 680 | 0.350 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2017 | 491 | 0.350 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2022 | 2865 | 0.350 |
Why?
|
| Organoplatinum Compounds | 4 | 2017 | 407 | 0.350 |
Why?
|
| Treatment Failure | 9 | 2013 | 2645 | 0.340 |
Why?
|
| Hemorrhage | 3 | 2022 | 3424 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2024 | 17904 | 0.340 |
Why?
|
| Transcription Factors | 10 | 2023 | 12128 | 0.340 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 795 | 0.340 |
Why?
|
| Odds Ratio | 18 | 2022 | 9646 | 0.330 |
Why?
|
| Polyethylene Glycols | 5 | 2022 | 1189 | 0.330 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 2735 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 410 | 0.320 |
Why?
|
| Diphosphonates | 1 | 2014 | 636 | 0.320 |
Why?
|
| Endonucleases | 3 | 2017 | 371 | 0.320 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2006 | 94 | 0.320 |
Why?
|
| Brachytherapy | 10 | 2018 | 1223 | 0.320 |
Why?
|
| Biomedical Research | 2 | 2022 | 3429 | 0.310 |
Why?
|
| Venous Thromboembolism | 4 | 2022 | 1866 | 0.310 |
Why?
|
| Predictive Value of Tests | 19 | 2024 | 15266 | 0.310 |
Why?
|
| Metformin | 1 | 2016 | 906 | 0.310 |
Why?
|
| Sarcoma | 1 | 2019 | 1801 | 0.310 |
Why?
|
| Liver Neoplasms | 6 | 2023 | 4320 | 0.310 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 2 | 2022 | 259 | 0.310 |
Why?
|
| Sodium | 1 | 2013 | 1588 | 0.300 |
Why?
|
| Marital Status | 5 | 2016 | 426 | 0.300 |
Why?
|
| Weight Loss | 1 | 2019 | 2684 | 0.290 |
Why?
|
| Hospitals | 8 | 2023 | 3882 | 0.290 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 2244 | 0.280 |
Why?
|
| Prostate | 7 | 2022 | 1770 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 15936 | 0.280 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 496 | 0.280 |
Why?
|
| Insurance, Health | 5 | 2019 | 2498 | 0.280 |
Why?
|
| Watchful Waiting | 4 | 2020 | 491 | 0.280 |
Why?
|
| Interferon-alpha | 3 | 2018 | 921 | 0.280 |
Why?
|
| Drug Delivery Systems | 6 | 2011 | 2226 | 0.270 |
Why?
|
| Analgesics | 1 | 2013 | 1070 | 0.270 |
Why?
|
| Age Factors | 20 | 2020 | 18395 | 0.270 |
Why?
|
| Forecasting | 5 | 2019 | 2928 | 0.270 |
Why?
|
| DNA Methylation | 10 | 2024 | 4398 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2022 | 20570 | 0.260 |
Why?
|
| Acute Kidney Injury | 4 | 2021 | 1924 | 0.260 |
Why?
|
| Cryosurgery | 1 | 2011 | 474 | 0.260 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2018 | 1148 | 0.260 |
Why?
|
| Single-Blind Method | 2 | 2020 | 1572 | 0.260 |
Why?
|
| Interleukin-2 | 4 | 2015 | 1889 | 0.260 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2010 | 748 | 0.260 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 2425 | 0.250 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2020 | 682 | 0.250 |
Why?
|
| Multivariate Analysis | 17 | 2018 | 12059 | 0.250 |
Why?
|
| Interleukin-7 | 2 | 2022 | 143 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2022 | 4580 | 0.250 |
Why?
|
| RNA, Neoplasm | 4 | 2016 | 750 | 0.250 |
Why?
|
| DNA Copy Number Variations | 10 | 2023 | 2020 | 0.250 |
Why?
|
| Recurrence | 8 | 2021 | 8465 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 4 | 2020 | 2645 | 0.240 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 946 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2244 | 0.240 |
Why?
|
| Thalidomide | 2 | 2006 | 885 | 0.230 |
Why?
|
| Ureteral Neoplasms | 2 | 2016 | 106 | 0.230 |
Why?
|
| Platinum Compounds | 3 | 2017 | 95 | 0.230 |
Why?
|
| Paclitaxel | 6 | 2019 | 1732 | 0.230 |
Why?
|
| Kallikreins | 4 | 2018 | 220 | 0.230 |
Why?
|
| Gene Expression | 7 | 2022 | 7581 | 0.220 |
Why?
|
| Osteoporosis | 1 | 2013 | 1606 | 0.220 |
Why?
|
| Cell Line, Tumor | 10 | 2023 | 16981 | 0.220 |
Why?
|
| Hemoglobins | 5 | 2017 | 1525 | 0.220 |
Why?
|
| Rare Diseases | 2 | 2020 | 622 | 0.220 |
Why?
|
| Genome-Wide Association Study | 7 | 2024 | 12690 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 2455 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 9 | 2018 | 3595 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 2057 | 0.220 |
Why?
|
| Kidney | 10 | 2023 | 7048 | 0.220 |
Why?
|
| Models, Biological | 5 | 2013 | 9469 | 0.220 |
Why?
|
| Telemedicine | 4 | 2021 | 3051 | 0.220 |
Why?
|
| Tissue Extracts | 2 | 2017 | 141 | 0.220 |
Why?
|
| Genome, Human | 5 | 2018 | 4425 | 0.220 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 21012 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 1115 | 0.210 |
Why?
|
| Hypothyroidism | 2 | 2018 | 668 | 0.210 |
Why?
|
| Socioeconomic Factors | 11 | 2020 | 7827 | 0.210 |
Why?
|
| ROC Curve | 4 | 2024 | 3579 | 0.210 |
Why?
|
| Postoperative Complications | 6 | 2017 | 15631 | 0.210 |
Why?
|
| Quinazolines | 4 | 2014 | 1371 | 0.210 |
Why?
|
| Health Services Accessibility | 5 | 2023 | 5440 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 3245 | 0.200 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2024 | 155 | 0.200 |
Why?
|
| Fatigue | 3 | 2019 | 1552 | 0.200 |
Why?
|
| International Cooperation | 5 | 2020 | 1422 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 7407 | 0.200 |
Why?
|
| HLA-A3 Antigen | 1 | 2021 | 34 | 0.200 |
Why?
|
| Boston | 3 | 2024 | 9326 | 0.200 |
Why?
|
| Penile Neoplasms | 1 | 2023 | 161 | 0.200 |
Why?
|
| Ischemia | 1 | 2010 | 1882 | 0.200 |
Why?
|
| Canada | 4 | 2024 | 2122 | 0.200 |
Why?
|
| Phthalazines | 1 | 2024 | 383 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 4 | 2021 | 2176 | 0.190 |
Why?
|
| Adjuvants, Immunologic | 2 | 2024 | 1036 | 0.190 |
Why?
|
| Up-Regulation | 3 | 2022 | 4124 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2020 | 326 | 0.190 |
Why?
|
| Insurance Coverage | 4 | 2019 | 1940 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2273 | 0.190 |
Why?
|
| Adenoma | 1 | 2012 | 2160 | 0.190 |
Why?
|
| Amylases | 2 | 2019 | 171 | 0.190 |
Why?
|
| Butylamines | 1 | 2021 | 9 | 0.190 |
Why?
|
| Genealogy and Heraldry | 1 | 2021 | 29 | 0.190 |
Why?
|
| Lymphocyte Count | 3 | 2024 | 778 | 0.190 |
Why?
|
| Medically Uninsured | 3 | 2016 | 836 | 0.190 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2021 | 82 | 0.190 |
Why?
|
| Erythropoietin | 2 | 2021 | 719 | 0.190 |
Why?
|
| Benzoxazoles | 1 | 2022 | 90 | 0.180 |
Why?
|
| Diarrhea | 2 | 2019 | 1318 | 0.180 |
Why?
|
| Immune System Diseases | 1 | 2023 | 256 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2017 | 1784 | 0.180 |
Why?
|
| Myocarditis | 2 | 2019 | 788 | 0.180 |
Why?
|
| Models, Statistical | 1 | 2015 | 5079 | 0.180 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 1271 | 0.180 |
Why?
|
| Receptors, Androgen | 3 | 2022 | 1079 | 0.180 |
Why?
|
| Aminoquinolines | 1 | 2021 | 107 | 0.180 |
Why?
|
| Minority Health | 2 | 2019 | 79 | 0.180 |
Why?
|
| Guidelines as Topic | 3 | 2015 | 1386 | 0.180 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2002 | 141 | 0.180 |
Why?
|
| Lymphatic Metastasis | 7 | 2017 | 2915 | 0.180 |
Why?
|
| Health Expenditures | 3 | 2020 | 2366 | 0.180 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 33 | 0.180 |
Why?
|
| Cause of Death | 10 | 2022 | 3683 | 0.180 |
Why?
|
| Aromatase Inhibitors | 1 | 2004 | 513 | 0.180 |
Why?
|
| Telomerase | 2 | 2024 | 745 | 0.180 |
Why?
|
| Heart Failure | 4 | 2014 | 11669 | 0.180 |
Why?
|
| Pneumonia | 1 | 2012 | 2143 | 0.170 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 4111 | 0.170 |
Why?
|
| Georgia | 1 | 2020 | 185 | 0.170 |
Why?
|
| Hypertension | 6 | 2022 | 8540 | 0.170 |
Why?
|
| Comparative Effectiveness Research | 3 | 2020 | 709 | 0.170 |
Why?
|
| Cell Respiration | 1 | 2020 | 201 | 0.170 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2021 | 150 | 0.170 |
Why?
|
| Camptothecin | 1 | 2023 | 591 | 0.170 |
Why?
|
| Radiography | 3 | 2016 | 6965 | 0.170 |
Why?
|
| Thyroid Neoplasms | 2 | 2024 | 2332 | 0.170 |
Why?
|
| Phenotype | 11 | 2023 | 16591 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 5 | 2021 | 883 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 161 | 0.170 |
Why?
|
| Cancer Care Facilities | 3 | 2017 | 422 | 0.170 |
Why?
|
| Databases, Genetic | 3 | 2021 | 1742 | 0.160 |
Why?
|
| Penetrance | 1 | 2021 | 383 | 0.160 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2019 | 128 | 0.160 |
Why?
|
| Lipase | 2 | 2019 | 325 | 0.160 |
Why?
|
| Genes, Neoplasm | 1 | 2021 | 370 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 2 | 2024 | 2895 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 367 | 0.160 |
Why?
|
| Therapeutics | 1 | 2019 | 113 | 0.160 |
Why?
|
| Regression Analysis | 7 | 2017 | 6343 | 0.160 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 5821 | 0.160 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2020 | 101 | 0.160 |
Why?
|
| Viruses | 1 | 2022 | 375 | 0.160 |
Why?
|
| Drugs, Investigational | 1 | 2021 | 212 | 0.160 |
Why?
|
| Spain | 1 | 2020 | 487 | 0.160 |
Why?
|
| Biology | 1 | 2021 | 290 | 0.160 |
Why?
|
| Alanine Transaminase | 2 | 2019 | 603 | 0.160 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 2578 | 0.160 |
Why?
|
| Income | 4 | 2014 | 1877 | 0.160 |
Why?
|
| Adolescent | 16 | 2024 | 88319 | 0.160 |
Why?
|
| Tyrosine | 1 | 2023 | 1440 | 0.160 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2002 | 242 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 4 | 2020 | 2020 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 535 | 0.150 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 502 | 0.150 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 899 | 0.150 |
Why?
|
| Quantitative Trait Loci | 2 | 2024 | 2116 | 0.150 |
Why?
|
| Observer Variation | 3 | 2015 | 2606 | 0.150 |
Why?
|
| Hospital Costs | 2 | 2016 | 947 | 0.150 |
Why?
|
| Divorce | 1 | 2018 | 75 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2023 | 2510 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2018 | 106 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 339 | 0.150 |
Why?
|
| Drug Repositioning | 1 | 2020 | 233 | 0.150 |
Why?
|
| Glutathione Peroxidase | 1 | 2019 | 258 | 0.150 |
Why?
|
| Receptor, erbB-2 | 5 | 2016 | 2557 | 0.150 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 142 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2011 | 2751 | 0.150 |
Why?
|
| Robotics | 3 | 2014 | 819 | 0.150 |
Why?
|
| Chromosome Deletion | 2 | 2020 | 1386 | 0.150 |
Why?
|
| Gene Dosage | 4 | 2015 | 1217 | 0.150 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2017 | 52 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
| Medicare | 6 | 2019 | 6770 | 0.140 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 117 | 0.140 |
Why?
|
| Platinum | 2 | 2015 | 220 | 0.140 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 3530 | 0.140 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 481 | 0.140 |
Why?
|
| Histone Demethylases | 1 | 2020 | 320 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 3205 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2024 | 1606 | 0.140 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 201 | 0.140 |
Why?
|
| Multiple Myeloma | 4 | 2007 | 5146 | 0.140 |
Why?
|
| Travel | 1 | 2023 | 796 | 0.140 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 37 | 0.140 |
Why?
|
| Warfarin | 2 | 2022 | 1483 | 0.140 |
Why?
|
| Cadherins | 1 | 2021 | 903 | 0.140 |
Why?
|
| Animals | 23 | 2024 | 168459 | 0.140 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 640 | 0.140 |
Why?
|
| Gene Deletion | 3 | 2020 | 2665 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2022 | 558 | 0.140 |
Why?
|
| Radioisotopes | 1 | 2018 | 499 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2018 | 357 | 0.140 |
Why?
|
| Smoking | 3 | 2024 | 9053 | 0.140 |
Why?
|
| Cost of Illness | 3 | 2015 | 1936 | 0.140 |
Why?
|
| Thrombosis | 1 | 2010 | 2942 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 5 | 2021 | 4740 | 0.140 |
Why?
|
| Seminoma | 2 | 2015 | 134 | 0.130 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2016 | 37 | 0.130 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 10194 | 0.130 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 66 | 0.130 |
Why?
|
| Muscle Neoplasms | 1 | 2017 | 130 | 0.130 |
Why?
|
| Venous Thrombosis | 2 | 2003 | 1303 | 0.130 |
Why?
|
| Retreatment | 4 | 2021 | 598 | 0.130 |
Why?
|
| Chemokine CXCL9 | 1 | 2016 | 135 | 0.130 |
Why?
|
| Synovitis | 1 | 2017 | 217 | 0.130 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 784 | 0.130 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 727 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2018 | 2919 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 1435 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2020 | 2469 | 0.130 |
Why?
|
| Biopsy | 6 | 2019 | 6766 | 0.130 |
Why?
|
| Health Status | 3 | 2022 | 4077 | 0.130 |
Why?
|
| Publication Bias | 2 | 2014 | 160 | 0.130 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 69 | 0.130 |
Why?
|
| Complementarity Determining Regions | 1 | 2016 | 149 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 641 | 0.130 |
Why?
|
| Colorectal Neoplasms | 7 | 2021 | 6935 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2021 | 858 | 0.130 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 97 | 0.130 |
Why?
|
| Multigene Family | 1 | 2018 | 1076 | 0.130 |
Why?
|
| Vaccines, Subunit | 1 | 2016 | 161 | 0.130 |
Why?
|
| Protein Kinases | 2 | 2015 | 1608 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 983 | 0.130 |
Why?
|
| Obesity | 3 | 2022 | 12947 | 0.130 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 2759 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 988 | 0.120 |
Why?
|
| Chi-Square Distribution | 5 | 2018 | 3416 | 0.120 |
Why?
|
| Health Status Disparities | 3 | 2023 | 1852 | 0.120 |
Why?
|
| Epidemiologic Studies | 2 | 2021 | 675 | 0.120 |
Why?
|
| Research | 1 | 2024 | 1982 | 0.120 |
Why?
|
| Air Pollution, Indoor | 1 | 2022 | 901 | 0.120 |
Why?
|
| Disease Management | 5 | 2020 | 2508 | 0.120 |
Why?
|
| Creatinine | 2 | 2020 | 1899 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 3712 | 0.120 |
Why?
|
| Body Mass Index | 6 | 2022 | 12953 | 0.120 |
Why?
|
| Proteinuria | 1 | 2018 | 607 | 0.120 |
Why?
|
| Health Care Costs | 3 | 2020 | 3242 | 0.120 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 316 | 0.120 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2014 | 43 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2018 | 549 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2020 | 851 | 0.120 |
Why?
|
| Piperazines | 2 | 2024 | 2523 | 0.120 |
Why?
|
| Piperidines | 2 | 2014 | 1656 | 0.120 |
Why?
|
| Interferon-gamma | 3 | 2020 | 3162 | 0.120 |
Why?
|
| Antigen Presentation | 1 | 2020 | 1251 | 0.120 |
Why?
|
| Accidents | 1 | 2015 | 165 | 0.120 |
Why?
|
| Mucositis | 1 | 2015 | 108 | 0.120 |
Why?
|
| Comorbidity | 7 | 2021 | 10508 | 0.120 |
Why?
|
| Bone Remodeling | 1 | 2018 | 581 | 0.120 |
Why?
|
| Placebos | 3 | 2017 | 1667 | 0.120 |
Why?
|
| Confidence Intervals | 3 | 2015 | 2927 | 0.120 |
Why?
|
| Filgrastim | 1 | 2014 | 132 | 0.120 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2014 | 106 | 0.120 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 795 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2020 | 1188 | 0.110 |
Why?
|
| Heart Neoplasms | 1 | 2017 | 362 | 0.110 |
Why?
|
| Drug Approval | 1 | 2021 | 814 | 0.110 |
Why?
|
| Insurance Benefits | 1 | 2016 | 187 | 0.110 |
Why?
|
| Doxorubicin | 2 | 2014 | 2224 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2018 | 6534 | 0.110 |
Why?
|
| Drug Therapy | 2 | 2014 | 503 | 0.110 |
Why?
|
| Quality of Health Care | 3 | 2019 | 4330 | 0.110 |
Why?
|
| Video Recording | 1 | 2019 | 966 | 0.110 |
Why?
|
| Suicide | 2 | 2015 | 1601 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 1705 | 0.110 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 23 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2020 | 1320 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2018 | 567 | 0.110 |
Why?
|
| Urban Population | 1 | 2022 | 2036 | 0.110 |
Why?
|
| Perioperative Care | 2 | 2019 | 1033 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 74 | 0.110 |
Why?
|
| Germ Cells | 3 | 2022 | 634 | 0.110 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 15500 | 0.110 |
Why?
|
| Geriatrics | 1 | 2018 | 388 | 0.110 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 754 | 0.110 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 72 | 0.110 |
Why?
|
| Drug Therapy, Combination | 5 | 2020 | 6310 | 0.110 |
Why?
|
| Apoptosis | 3 | 2019 | 9486 | 0.110 |
Why?
|
| Radiotherapy | 4 | 2017 | 1499 | 0.110 |
Why?
|
| Muscles | 1 | 2018 | 1576 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1440 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 132 | 0.110 |
Why?
|
| Liver Function Tests | 1 | 2014 | 523 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 2017 | 926 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 789 | 0.110 |
Why?
|
| Morpholines | 1 | 2016 | 581 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 126 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 372 | 0.100 |
Why?
|
| Propensity Score | 5 | 2019 | 1913 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2015 | 590 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2018 | 1187 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2021 | 1126 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2017 | 1416 | 0.100 |
Why?
|
| Epigenesis, Genetic | 4 | 2024 | 3802 | 0.100 |
Why?
|
| Hypocalcemia | 1 | 2014 | 200 | 0.100 |
Why?
|
| Heme Oxygenase-1 | 1 | 2015 | 366 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2013 | 165 | 0.100 |
Why?
|
| Urology | 1 | 2017 | 400 | 0.100 |
Why?
|
| Aminopyridines | 1 | 2016 | 573 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2015 | 672 | 0.100 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 700 | 0.100 |
Why?
|
| MicroRNAs | 4 | 2016 | 3816 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 231 | 0.100 |
Why?
|
| Lymph Nodes | 4 | 2017 | 3466 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 7390 | 0.100 |
Why?
|
| Vaccination | 2 | 2021 | 3384 | 0.100 |
Why?
|
| Epidemiologic Methods | 3 | 2015 | 1336 | 0.100 |
Why?
|
| Alleles | 4 | 2021 | 6863 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2016 | 1596 | 0.100 |
Why?
|
| Penis | 1 | 2013 | 212 | 0.100 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 779 | 0.100 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1745 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 791 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 1459 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2022 | 2009 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 1640 | 0.090 |
Why?
|
| Community Health Services | 1 | 2016 | 656 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2021 | 4003 | 0.090 |
Why?
|
| Rural Population | 1 | 2022 | 2285 | 0.090 |
Why?
|
| Genotype | 3 | 2015 | 12990 | 0.090 |
Why?
|
| Telomere | 1 | 2017 | 943 | 0.090 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2016 | 209 | 0.090 |
Why?
|
| Treatment Refusal | 1 | 2014 | 429 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 3826 | 0.090 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 1410 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2298 | 0.090 |
Why?
|
| Minority Groups | 1 | 2018 | 1203 | 0.090 |
Why?
|
| Postoperative Period | 2 | 2018 | 1813 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 506 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 1039 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 2691 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1896 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2018 | 2020 | 0.090 |
Why?
|
| Metabolomics | 1 | 2019 | 1659 | 0.090 |
Why?
|
| Mass Screening | 3 | 2021 | 5428 | 0.090 |
Why?
|
| Sex Factors | 7 | 2020 | 10552 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2021 | 2882 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2022 | 4812 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2016 | 962 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 598 | 0.080 |
Why?
|
| Enteritis | 1 | 2011 | 162 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 4174 | 0.080 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 561 | 0.080 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 1515 | 0.080 |
Why?
|
| Cancer Vaccines | 3 | 2016 | 1051 | 0.080 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 20098 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 678 | 0.080 |
Why?
|
| Arteries | 2 | 2012 | 1123 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 225 | 0.080 |
Why?
|
| Neutropenia | 2 | 2012 | 885 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2013 | 2219 | 0.080 |
Why?
|
| Heart Conduction System | 1 | 2014 | 1007 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3688 | 0.080 |
Why?
|
| Remission Induction | 1 | 2015 | 2396 | 0.080 |
Why?
|
| Oxygen | 1 | 2020 | 4227 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 633 | 0.080 |
Why?
|
| Anemia, Macrocytic | 1 | 2008 | 53 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 1200 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2018 | 3442 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2015 | 2220 | 0.080 |
Why?
|
| Prednisone | 2 | 2023 | 1563 | 0.080 |
Why?
|
| Methionine | 1 | 2010 | 572 | 0.080 |
Why?
|
| Cardiology | 1 | 2019 | 1656 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 4026 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 809 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1802 | 0.070 |
Why?
|
| Hospice Care | 1 | 2015 | 678 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2015 | 36426 | 0.070 |
Why?
|
| Nitriles | 2 | 2021 | 971 | 0.070 |
Why?
|
| Karyotyping | 1 | 2009 | 1171 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2014 | 1096 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 186 | 0.070 |
Why?
|
| Laparoscopy | 3 | 2019 | 2035 | 0.070 |
Why?
|
| Macrophages | 3 | 2021 | 5769 | 0.070 |
Why?
|
| Patient Admission | 1 | 2015 | 1367 | 0.070 |
Why?
|
| Methotrexate | 1 | 2014 | 1719 | 0.070 |
Why?
|
| Acetaminophen | 1 | 2011 | 554 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 1246 | 0.070 |
Why?
|
| Paxillin | 1 | 2007 | 86 | 0.070 |
Why?
|
| Demography | 3 | 2018 | 1648 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2024 | 4811 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2011 | 683 | 0.070 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2012 | 1007 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2008 | 111 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7594 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5294 | 0.070 |
Why?
|
| Genetic Variation | 3 | 2022 | 6567 | 0.070 |
Why?
|
| Proteomics | 2 | 2017 | 3849 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 2007 | 223 | 0.070 |
Why?
|
| Child | 6 | 2021 | 80153 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2021 | 8320 | 0.070 |
Why?
|
| RNA, Messenger | 6 | 2016 | 12795 | 0.070 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 11460 | 0.070 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2006 | 46 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2022 | 3600 | 0.070 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 426 | 0.070 |
Why?
|
| Urethra | 1 | 2008 | 405 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5247 | 0.070 |
Why?
|
| Diffusion of Innovation | 1 | 2011 | 728 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 411 | 0.070 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2006 | 61 | 0.070 |
Why?
|
| Endothelins | 1 | 2006 | 127 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 1334 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2007 | 256 | 0.060 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 26125 | 0.060 |
Why?
|
| Karnofsky Performance Status | 2 | 2017 | 166 | 0.060 |
Why?
|
| Biological Products | 1 | 2014 | 914 | 0.060 |
Why?
|
| Radiology | 1 | 2019 | 2113 | 0.060 |
Why?
|
| Chromatin | 2 | 2016 | 2960 | 0.060 |
Why?
|
| Daptomycin | 1 | 2005 | 71 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2020 | 4278 | 0.060 |
Why?
|
| Dementia | 1 | 2019 | 2686 | 0.060 |
Why?
|
| Chorionic Gonadotropin | 1 | 2007 | 457 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 360 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 498 | 0.060 |
Why?
|
| Interferons | 1 | 2008 | 706 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2024 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1998 | 0.060 |
Why?
|
| Enterococcus faecium | 1 | 2005 | 101 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 1897 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2013 | 2448 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1376 | 0.060 |
Why?
|
| Carboplatin | 2 | 2020 | 794 | 0.060 |
Why?
|
| Eligibility Determination | 2 | 2021 | 421 | 0.060 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 846 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 14605 | 0.060 |
Why?
|
| Activated Protein C Resistance | 1 | 2003 | 18 | 0.060 |
Why?
|
| Case-Control Studies | 6 | 2024 | 22176 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2006 | 338 | 0.060 |
Why?
|
| Medical Records | 1 | 2009 | 1408 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1702 | 0.060 |
Why?
|
| Random Allocation | 2 | 2019 | 2395 | 0.060 |
Why?
|
| DNA Primers | 1 | 2008 | 2819 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 6075 | 0.060 |
Why?
|
| Sphingosine | 1 | 2006 | 308 | 0.060 |
Why?
|
| Weight Gain | 1 | 2014 | 2348 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 2651 | 0.060 |
Why?
|
| Lysophospholipids | 1 | 2006 | 338 | 0.050 |
Why?
|
| Genetic Heterogeneity | 2 | 2018 | 732 | 0.050 |
Why?
|
| INDEL Mutation | 2 | 2015 | 266 | 0.050 |
Why?
|
| Castration | 1 | 2023 | 151 | 0.050 |
Why?
|
| Levivirus | 1 | 2023 | 14 | 0.050 |
Why?
|
| Terminal Care | 1 | 2015 | 1760 | 0.050 |
Why?
|
| Testosterone | 1 | 2014 | 2472 | 0.050 |
Why?
|
| Factor V | 1 | 2003 | 167 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2013 | 1909 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 1181 | 0.050 |
Why?
|
| Survival | 2 | 2013 | 161 | 0.050 |
Why?
|
| Oximes | 1 | 2024 | 303 | 0.050 |
Why?
|
| Caspases | 1 | 2006 | 879 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2013 | 2568 | 0.050 |
Why?
|
| Overweight | 1 | 2014 | 2417 | 0.050 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2005 | 343 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 3076 | 0.050 |
Why?
|
| Prevalence | 4 | 2021 | 15732 | 0.050 |
Why?
|
| Androstadienes | 1 | 2004 | 348 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5336 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 5368 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 178 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 1007 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2005 | 694 | 0.050 |
Why?
|
| Drug Costs | 1 | 2010 | 1183 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 3763 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 12974 | 0.050 |
Why?
|
| Lymphopenia | 1 | 2024 | 281 | 0.050 |
Why?
|
| Tennessee | 1 | 2021 | 120 | 0.050 |
Why?
|
| Free Radicals | 1 | 2002 | 238 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2010 | 2135 | 0.050 |
Why?
|
| Aging | 2 | 2018 | 8708 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3728 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2024 | 586 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2023 | 3113 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 2006 | 2208 | 0.050 |
Why?
|
| Nutrition Disorders | 1 | 2022 | 205 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1626 | 0.050 |
Why?
|
| London | 1 | 2021 | 234 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 1134 | 0.050 |
Why?
|
| Urinary Bladder | 2 | 2017 | 1152 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2021 | 56 | 0.050 |
Why?
|
| Paraproteinemias | 1 | 2003 | 248 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 42230 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2011 | 2911 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 202 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2017 | 4686 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2022 | 344 | 0.040 |
Why?
|
| Liver | 2 | 2013 | 7529 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2019 | 3615 | 0.040 |
Why?
|
| Morbidity | 2 | 2017 | 1750 | 0.040 |
Why?
|
| ras Proteins | 2 | 2016 | 1054 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2002 | 382 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 15842 | 0.040 |
Why?
|
| Inpatients | 1 | 2012 | 2548 | 0.040 |
Why?
|
| Length of Stay | 4 | 2017 | 6425 | 0.040 |
Why?
|
| Vincristine | 1 | 2002 | 1036 | 0.040 |
Why?
|
| Japan | 2 | 2015 | 1378 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 3461 | 0.040 |
Why?
|
| Probability | 2 | 2020 | 2477 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2014 | 5914 | 0.040 |
Why?
|
| Pelvis | 2 | 2017 | 732 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 164 | 0.040 |
Why?
|
| Androstenes | 1 | 2021 | 181 | 0.040 |
Why?
|
| Self Report | 3 | 2016 | 3724 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2024 | 617 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2021 | 205 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 551 | 0.040 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 423 | 0.040 |
Why?
|
| Age of Onset | 3 | 2015 | 3305 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 694 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2002 | 305 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 223 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 1085 | 0.040 |
Why?
|
| Anxiety | 1 | 2014 | 4573 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2021 | 522 | 0.040 |
Why?
|
| History, 21st Century | 2 | 2015 | 1567 | 0.040 |
Why?
|
| Benzamides | 2 | 2021 | 1370 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2003 | 706 | 0.040 |
Why?
|
| Massachusetts | 3 | 2021 | 8830 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 469 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 362 | 0.040 |
Why?
|
| Kynurenine | 1 | 2019 | 141 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 356 | 0.040 |
Why?
|
| Granzymes | 1 | 2020 | 277 | 0.040 |
Why?
|
| Triazoles | 1 | 2004 | 903 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 199 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 231 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7856 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2021 | 360 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 678 | 0.040 |
Why?
|
| Th1-Th2 Balance | 1 | 2018 | 38 | 0.040 |
Why?
|
| Hospitalization | 2 | 2015 | 10723 | 0.040 |
Why?
|
| Furans | 1 | 2019 | 202 | 0.040 |
Why?
|
| Paresthesia | 1 | 2019 | 162 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2707 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2024 | 5789 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 2471 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2019 | 271 | 0.040 |
Why?
|
| Haplotypes | 1 | 2024 | 2713 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 1048 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 849 | 0.040 |
Why?
|
| Mammography | 2 | 2021 | 2430 | 0.040 |
Why?
|
| Public Health | 2 | 2021 | 2669 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 609 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 482 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2015 | 2767 | 0.040 |
Why?
|
| Models, Economic | 2 | 2012 | 716 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2017 | 92 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 288 | 0.040 |
Why?
|
| Anemia | 1 | 2006 | 1509 | 0.040 |
Why?
|
| Oncogenes | 1 | 2023 | 1222 | 0.030 |
Why?
|
| Patient Care Team | 2 | 2022 | 2521 | 0.030 |
Why?
|
| Troponin T | 1 | 2022 | 780 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 2218 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2014 | 2281 | 0.030 |
Why?
|
| Plasma | 1 | 2020 | 586 | 0.030 |
Why?
|
| Health Facilities | 1 | 2022 | 580 | 0.030 |
Why?
|
| HIV Infections | 1 | 2023 | 17351 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 790 | 0.030 |
Why?
|
| Organ Size | 2 | 2013 | 2254 | 0.030 |
Why?
|
| Educational Status | 2 | 2014 | 2522 | 0.030 |
Why?
|
| Cricetulus | 1 | 2018 | 814 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 8124 | 0.030 |
Why?
|
| Marriage | 1 | 2018 | 351 | 0.030 |
Why?
|
| Social Class | 2 | 2016 | 2004 | 0.030 |
Why?
|
| Computational Biology | 2 | 2019 | 3518 | 0.030 |
Why?
|
| Korea | 1 | 2015 | 98 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2017 | 159 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2021 | 1093 | 0.030 |
Why?
|
| Philippines | 1 | 2015 | 90 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 802 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2024 | 11528 | 0.030 |
Why?
|
| Antibodies | 1 | 2024 | 2418 | 0.030 |
Why?
|
| DNA Repair | 2 | 2015 | 2045 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2872 | 0.030 |
Why?
|
| Mortality | 2 | 2019 | 2901 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 297 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2023 | 1616 | 0.030 |
Why?
|
| CHO Cells | 1 | 2018 | 1387 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2330 | 0.030 |
Why?
|
| Cost Sharing | 1 | 2019 | 409 | 0.030 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2015 | 122 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2015 | 131 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1516 | 0.030 |
Why?
|
| Epidemics | 1 | 2021 | 512 | 0.030 |
Why?
|
| Fumarate Hydratase | 1 | 2015 | 52 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 189 | 0.030 |
Why?
|
| Vietnam | 1 | 2015 | 409 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2015 | 160 | 0.030 |
Why?
|
| Heparin | 1 | 2002 | 1634 | 0.030 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2015 | 162 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 9000 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 2825 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 93 | 0.030 |
Why?
|
| Syndrome | 1 | 2021 | 3267 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2017 | 458 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2015 | 397 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2022 | 834 | 0.030 |
Why?
|
| Acute Disease | 2 | 2021 | 7237 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1661 | 0.030 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2015 | 125 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 243 | 0.030 |
Why?
|
| Cell Line | 2 | 2020 | 15601 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2017 | 369 | 0.030 |
Why?
|
| Goserelin | 1 | 2014 | 126 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2014 | 170 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2014 | 1188 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 6485 | 0.030 |
Why?
|
| Gilbert Disease | 1 | 2013 | 4 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 1410 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2024 | 2639 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 463 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2016 | 290 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2020 | 2358 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2014 | 5439 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1722 | 0.030 |
Why?
|
| Pedigree | 1 | 2021 | 4542 | 0.030 |
Why?
|
| Brazil | 1 | 2017 | 1230 | 0.030 |
Why?
|
| Cost Savings | 1 | 2019 | 913 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 305 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2014 | 6228 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2017 | 461 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 619 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 1076 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1379 | 0.030 |
Why?
|
| Cardiotoxins | 1 | 2013 | 36 | 0.030 |
Why?
|
| Genome | 1 | 2021 | 1740 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 3769 | 0.030 |
Why?
|
| Diaphragm | 1 | 2014 | 351 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 473 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 727 | 0.030 |
Why?
|
| Leuprolide | 1 | 2014 | 312 | 0.030 |
Why?
|
| Natural Language Processing | 1 | 2021 | 1162 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2021 | 1394 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1664 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 787 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 161 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 1301 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2017 | 1089 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 727 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 800 | 0.030 |
Why?
|
| Patient Readmission | 2 | 2017 | 3270 | 0.030 |
Why?
|
| Singapore | 1 | 2013 | 292 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2019 | 2601 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 441 | 0.030 |
Why?
|
| Immunity | 1 | 2018 | 996 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2019 | 2426 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1787 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2019 | 1242 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 1125 | 0.020 |
Why?
|
| Tumor Escape | 1 | 2015 | 370 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 2547 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 130 | 0.020 |
Why?
|
| Bilirubin | 1 | 2013 | 436 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2015 | 846 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 638 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2015 | 787 | 0.020 |
Why?
|
| Homozygote | 1 | 2016 | 1776 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 1421 | 0.020 |
Why?
|
| Office Visits | 1 | 2015 | 595 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2023 | 3065 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2019 | 8481 | 0.020 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2010 | 80 | 0.020 |
Why?
|
| Republic of Korea | 1 | 2013 | 590 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2015 | 1341 | 0.020 |
Why?
|
| CpG Islands | 1 | 2015 | 1230 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 805 | 0.020 |
Why?
|
| Denmark | 1 | 2013 | 771 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2020 | 2161 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2016 | 1328 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3602 | 0.020 |
Why?
|
| Internationality | 1 | 2016 | 1001 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2628 | 0.020 |
Why?
|
| Iron | 1 | 2019 | 1793 | 0.020 |
Why?
|
| Mice | 3 | 2024 | 81525 | 0.020 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2010 | 56 | 0.020 |
Why?
|
| RNA Interference | 1 | 2019 | 2831 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 1961 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 3080 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 1171 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 746 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2014 | 600 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Health Occupations | 1 | 2011 | 222 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 2898 | 0.020 |
Why?
|
| China | 1 | 2015 | 2369 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2009 | 48 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2010 | 395 | 0.020 |
Why?
|
| Leukocytes | 1 | 2017 | 2026 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 865 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 1155 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 3879 | 0.020 |
Why?
|
| Protein Transport | 1 | 2015 | 1967 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 5492 | 0.020 |
Why?
|
| Health Surveys | 1 | 2018 | 4061 | 0.020 |
Why?
|
| Research Design | 2 | 2014 | 6180 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2022 | 3745 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5112 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2917 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 504 | 0.020 |
Why?
|
| Norway | 1 | 2009 | 499 | 0.020 |
Why?
|
| Europe | 1 | 2015 | 3422 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2019 | 1730 | 0.020 |
Why?
|
| Military Personnel | 1 | 2017 | 1246 | 0.020 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2008 | 79 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2008 | 144 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2018 | 2690 | 0.020 |
Why?
|
| Alberta | 1 | 2007 | 68 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1768 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2017 | 2632 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2010 | 597 | 0.020 |
Why?
|
| Quebec | 1 | 2007 | 141 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3060 | 0.020 |
Why?
|
| Lipids | 1 | 2019 | 3341 | 0.020 |
Why?
|
| Stroke | 1 | 2010 | 9757 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 1834 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2008 | 239 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2015 | 992 | 0.020 |
Why?
|
| Decision Making | 1 | 2021 | 3929 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 473 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2012 | 659 | 0.020 |
Why?
|
| Poland | 1 | 2007 | 198 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1745 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2020 | 3537 | 0.020 |
Why?
|
| Health Personnel | 1 | 2021 | 3335 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 1668 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 1156 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 6132 | 0.020 |
Why?
|
| Hormones | 1 | 2011 | 869 | 0.020 |
Why?
|
| Ohio | 1 | 2007 | 322 | 0.020 |
Why?
|
| Wound Healing | 1 | 2018 | 2805 | 0.020 |
Why?
|
| Internet | 1 | 2019 | 3092 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 3734 | 0.020 |
Why?
|
| Albuminuria | 1 | 2010 | 657 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 3968 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 162 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1463 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2021 | 9318 | 0.020 |
Why?
|
| Receptor, Endothelin A | 1 | 2006 | 56 | 0.020 |
Why?
|
| France | 1 | 2007 | 497 | 0.020 |
Why?
|
| DNA | 1 | 2020 | 7212 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1403 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 1197 | 0.020 |
Why?
|
| Receptors, Endothelin | 1 | 2006 | 56 | 0.020 |
Why?
|
| Sweden | 1 | 2009 | 1379 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 1624 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2007 | 148 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7396 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 6216 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2007 | 217 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 1792 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 550 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2013 | 868 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2015 | 3688 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 1436 | 0.020 |
Why?
|
| Exercise | 1 | 2002 | 5890 | 0.020 |
Why?
|
| Cognition | 1 | 2022 | 6990 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2571 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5791 | 0.010 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 801 | 0.010 |
Why?
|
| RNA | 1 | 2014 | 2726 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2006 | 302 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2019 | 6391 | 0.010 |
Why?
|
| Insulin | 1 | 2019 | 6596 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2014 | 2598 | 0.010 |
Why?
|
| Cartilage | 1 | 2007 | 806 | 0.010 |
Why?
|
| Social Support | 1 | 2013 | 2171 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2880 | 0.010 |
Why?
|
| Base Sequence | 1 | 2014 | 12441 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4618 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2016 | 6240 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 1900 | 0.010 |
Why?
|
| Cell Movement | 1 | 2014 | 5203 | 0.010 |
Why?
|
| Critical Care | 1 | 2015 | 2696 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2014 | 3575 | 0.010 |
Why?
|
| Androgens | 1 | 2010 | 1286 | 0.010 |
Why?
|
| Poverty | 1 | 2014 | 2698 | 0.010 |
Why?
|
| Myoglobin | 1 | 2002 | 159 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2006 | 1129 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 17635 | 0.010 |
Why?
|
| Veterans | 1 | 2015 | 2647 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2011 | 1797 | 0.010 |
Why?
|
| Mitochondria, Muscle | 1 | 2002 | 172 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 1405 | 0.010 |
Why?
|
| Rhabdomyolysis | 1 | 2002 | 152 | 0.010 |
Why?
|
| Emotions | 1 | 2013 | 2739 | 0.010 |
Why?
|
| Tretinoin | 1 | 2003 | 519 | 0.010 |
Why?
|
| Reoperation | 1 | 2010 | 4303 | 0.010 |
Why?
|
| Mental Health | 1 | 2014 | 3250 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 14031 | 0.010 |
Why?
|
| Physical Exertion | 1 | 2002 | 667 | 0.010 |
Why?
|
| Linear Models | 1 | 2008 | 5871 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 11903 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 1739 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2002 | 1201 | 0.010 |
Why?
|
| Heterozygote | 1 | 2003 | 2787 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 12148 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 10000 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2002 | 4948 | 0.000 |
Why?
|